Literature DB >> 3060046

The gerbil, Meriones unguiculatus, a model for Rift Valley fever viral encephalitis.

G W Anderson1, T W Slone, C J Peters.   

Abstract

The gerbil, Meriones unguiculatus, was investigated as a model for the encephalitic form of Rift Valley fever. Resistance to necrotizing encephalitis was age-dependent with 100% mortality at 3 weeks, decreasing to approximately 20% by 10 weeks of age in outbred gerbils inoculated subcutaneously. Fatal encephalitis in the 10-week-old adults was dose-independent [1.0-7.0 log10 plaque forming units (PFU), subcutaneously]. Viral replication and histological lesions were followed serially throughout the course of the infection in young (4 week) and adult (10 week) gerbils. Viral replication was evident in the brain tissue of young gerbils from day 4 (3.0 log10 PFU/g) through day 7 (6.0 log10 PFU/g), the last day the young gerbils survived. Virus was only detected in the brain tissue of a single adult gerbil (day 7, 4.0 log10 PFU/g) of 26 studied in the sequential survey. In contrast, two moribund adult gerbils had approximately 7.0 log10 PFU/g of virus in the brain tissue on days 8 and 11. When young and adult gerbils were inoculated with a low dose (50 PFU) of virus intracranially, there were no detectable differences in the course of infection with all animals succumbing to fatal necrotizing encephalitis approximately 7 days postinoculation. The young gerbil becomes the first animal model in which uniformly fatal RVFV-induced encephalitis is produced without significant extraneural lesions.

Entities:  

Mesh:

Year:  1988        PMID: 3060046     DOI: 10.1007/bf01310824

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  12 in total

1.  A plaque neutralization method for arboviruses.

Authors:  E Earley; P H Peralta; K M Johnson
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

2.  Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine.

Authors:  K C SMITHBURN
Journal:  Br J Exp Pathol       Date:  1949-02

3.  Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.

Authors:  C J Peters; J A Reynolds; T W Slone; D E Jones; E L Stephen
Journal:  Antiviral Res       Date:  1986-08       Impact factor: 5.970

4.  The development of neurotropism in Rift Valley fever virus.

Authors:  S F KITCHEN
Journal:  Ann Trop Med Parasitol       Date:  1950-07

5.  Clinical studies on Rift Valley fever. Part 2: Ophthalmologic and central nervous system complications.

Authors:  L W Laughlin; N I Girgis; J M Meegan; L J Strausbaugh; M W Yassin; R H Watten
Journal:  J Egypt Public Health Assoc       Date:  1978

6.  Neurovirulent Toscana virus (a sandfly fever virus) in Swedish man after visit to Portugal.

Authors:  A Ehrnst; C J Peters; B Niklasson; A Svedmyr; B Holmgren
Journal:  Lancet       Date:  1985-05-25       Impact factor: 79.321

7.  Morphogenesis of sandfly viruses (Bunyaviridae family).

Authors:  J F Smith; D Y Pifat
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

8.  Laboratory safety for arboviruses and certain other viruses of vertebrates. The Subcommittee on Arbovirus Laboratory Safety of the American Committee on Arthropod-Borne Viruses.

Authors: 
Journal:  Am J Trop Med Hyg       Date:  1980-11       Impact factor: 2.345

9.  Rift Valley fever encephalitis. A description of a case.

Authors:  S A Maar; R Swanepoel; M Gelfand
Journal:  Cent Afr J Med       Date:  1979-01

10.  Inbred rat strains mimic the disparate human response to Rift Valley fever virus infection.

Authors:  C J Peters; T W Slone
Journal:  J Med Virol       Date:  1982       Impact factor: 2.327

View more
  15 in total

Review 1.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

2.  Isolation of Borna disease virus from human brain tissue.

Authors:  Y Nakamura; H Takahashi; Y Shoya; T Nakaya; M Watanabe; K Tomonaga; K Iwahashi; K Ameno; N Momiyama; H Taniyama; T Sata; T Kurata; J C de la Torre; K Ikuta
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

3.  Development of a novel nonhuman primate model for Rift Valley fever.

Authors:  Darci R Smith; Brian H Bird; Bridget Lewis; Sara C Johnston; Sarah McCarthy; Ashley Keeney; Miriam Botto; Ginger Donnelly; Joshua Shamblin; César G Albariño; Stuart T Nichol; Lisa E Hensley
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 4.  Molecular biology and genetic diversity of Rift Valley fever virus.

Authors:  Tetsuro Ikegami
Journal:  Antiviral Res       Date:  2012-06-16       Impact factor: 5.970

5.  Pathogenesis of a phleboviral infection (Punta Toro virus) in golden Syrian hamsters.

Authors:  G W Anderson; M V Slayter; W Hall; C J Peters
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

6.  Genetic diversity of collaborative cross mice enables identification of novel rift valley fever virus encephalitis model.

Authors:  Haley N Cartwright; Dominique J Barbeau; Joshua D Doyle; Ed Klein; Mark T Heise; Martin T Ferris; Anita K McElroy
Journal:  PLoS Pathog       Date:  2022-07-14       Impact factor: 7.464

7.  Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.

Authors:  Sabarish V Indran; Olga A Lihoradova; Inaia Phoenix; Nandadeva Lokugamage; Birte Kalveram; Jennifer A Head; Bersabeh Tigabu; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Gen Virol       Date:  2013-03-20       Impact factor: 3.891

Review 8.  The pathogenesis of Rift Valley fever.

Authors:  Tetsuro Ikegami; Shinji Makino
Journal:  Viruses       Date:  2011-05       Impact factor: 5.048

9.  Rift Valley fever virus infection in golden Syrian hamsters.

Authors:  Dionna Scharton; Arnaud J Van Wettere; Kevin W Bailey; Zachary Vest; Jonna B Westover; Venkatraman Siddharthan; Brian B Gowen
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

10.  Rift Valley fever encephalitis.

Authors:  Abdulrahman A Alrajhi; Abdulaziz Al-Semari; Jehad Al-Watban
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.